Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly

Eli Lilly (NYSE:LLY) and Johnson & Johnson (NYSE:JNJ) conscionable reported Q1 2026 results that work similar 2 antithetic playbooks for winning successful healthcare. Lilly is riding a GLP-1 wave. JNJ is proving that a wide, refreshed portfolio tin inactive compound. Both raised guidance and some are worthy putting broadside by broadside close now.

GLP-1 Fireworks vs. a Deep Bench

Lilly posted $19.80 cardinal successful revenue, up 55.5% twelvemonth implicit year, with Mounjaro unsocial contributing $8.66 cardinal and Zepbound adding $4.16 billion. That is simply a staggering attraction successful metabolic drugs, and it delivered non-GAAP EPS of $8.55.

CEO David Ricks said "2026 is disconnected to a beardown start", spotlighting the FDA support of Foundayo, the archetypal oral GLP-1 pill without nutrient oregon h2o restrictions.

JNJ told a precise antithetic story. Revenue of $24.062 cardinal grew 9.9%, divided betwixt Innovative Medicine astatine $15.426 cardinal and MedTech astatine $8.636 billion. DARZALEX cleared $3.964 billion, TREMFYA jumped 68.3%, and cardiovascular MedTech roseate 13% connected Abiomed and Shockwave strength.

CEO Duato called the portfolio "unrivaled", pointing to ICOTYDE, the archetypal targeted oral peptide for plaque psoriasis.

Act now: the expert who called NVIDIA successful 2010 conscionable named his apical 10 AI stocks — and Eli Lilly didn't marque the cut. Grab the names FREE today.

One Company Concentrates, the Other Diversifies

Lilly is doubling down connected metabolic dominance. Ricks highlighted acquisitions of Orna, Centessa, Kelonia, and Ajax, positive a $6 cardinal Alabama works and an NVIDIA (NASDAQ:NVDA) drug-discovery lab. Guidance present sits astatine $82 to $85 cardinal successful gross and $35.50 to $37 EPS. The trailing P/E of 42 reflects that ambition, and the banal is up 56.86% implicit the past year.

JNJ is sharpening absorption by spinning disconnected DePuy Synthes orthopaedics wrong 18 to 24 months. Full-year guidance climbed to $100.3 to $101.3 cardinal with adjusted EPS of $11.45 to $11.65. The dividend roseate 3.1% to $1.34, marking 64 consecutive years of increases. Forward P/E of 22 and beta of 0.256 emblem it arsenic the calmer name.